5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | NEUTRAL | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.83▼ | 1.83▼ | 1.83▼ | 1.60▲ | 1.65▲ |
MA10 | 1.87▼ | 1.80▼ | 1.71▲ | 1.47▲ | 1.91▼ |
MA20 | 1.72▲ | 1.60▲ | 1.53▲ | 1.54▲ | 2.05▼ |
MA50 | 1.51▲ | 1.51▲ | 1.53▲ | 1.94▼ | 1.97▼ |
MA100 | 1.60▲ | 1.83▼ | 1.90▼ | 2.01▼ | 3.15▼ |
MA200 | 1.93▼ | 2.15▼ | 2.28▼ | 1.72▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.011▼ | 0.030▲ | 0.050▲ | 0.067▲ | -0.067▼ |
RSI | 53.651▲ | 56.077▲ | 56.529▲ | 52.906▲ | 47.507▼ |
STOCH | 40.597 | 57.667 | 64.105 | 53.410 | 25.578 |
WILL %R | -73.171 | -39.474 | -39.474 | -43.137 | -62.773 |
CCI | -63.935 | 32.493 | 48.647 | 151.727▲ | -62.015 |
Thursday, May 16, 2024 04:00 PM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
|
Thursday, May 16, 2024 07:52 AM
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve ...
|
Wednesday, May 15, 2024 07:00 PM
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/05/24 | 1.71 | 1.915 | 1.71 | 1.78 | 90,929 |
15/05/24 | 1.58 | 2.22 | 1.55 | 1.99 | 567,062 |
14/05/24 | 1.38 | 1.60 | 1.36 | 1.54 | 48,115 |
13/05/24 | 1.36 | 1.36 | 1.36 | 1.36 | 9,752 |
10/05/24 | 1.40 | 1.44 | 1.30 | 1.31 | 55,332 |
09/05/24 | 1.39 | 1.39 | 1.35 | 1.36 | 34,662 |
08/05/24 | 1.31 | 1.55 | 1.31 | 1.40 | 34,847 |
07/05/24 | 1.29 | 1.30 | 1.20 | 1.26 | 30,515 |
06/05/24 | 1.40 | 1.45 | 1.29 | 1.29 | 71,764 |
03/05/24 | 1.38 | 1.51 | 1.3304 | 1.39 | 46,966 |
|
|
||||
|
|
||||
|
|